Stockscreener 앱 받기
70.60
2.02%
1.40
시간 외 거래:
70.60
Edwards Lifesciences Corp 주식(EW)의 최신 뉴스
Edwards touts 8-year data for Resilia valve tissue - MassDevice
Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Edwards Lifesciences (EW) Shares Surge on Promising Aortic Valve Study Results | EW Stock News - GuruFocus
Breakthrough: Edwards Heart Valves Achieve 99.3% Success Rate in Landmark 8-Year Study - Stock Titan
Is Edwards Lifesciences Gaining or Losing Market Support? - Benzinga
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings - MSN
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025 - marketscreener.com
Edwards Lifesciences Insider Sold Shares Worth $663,196, According to a Recent SEC Filing - marketscreener.com
Edwards Lifesciences CVP Donald Bobo Jr. sells $663k in stock - Investing.com Australia
Edwards Lifesciences (EW) Secures CE Mark for Innovative Mitral Valve System | EW Stock News - GuruFocus
Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System - BioSpace
Edwards Lifesciences CVP Donald Bobo Jr. sells $663k in stock By Investing.com - Investing.com South Africa
Edwards lands first CE mark for transfemoral mitral valve replacement - BioWorld MedTech
Edwards Lifesciences Gets CE Mark for Sapien M3 Mitral Valve System - MarketScreener
Edwards Sapien M3 Receives CE Mark, Becoming World'S First Transfemoral Transcatheter Mitral Valve Replacement System - MarketScreener
Edwards wins CE mark for Sapien M3 transfemoral heart valve - MassDevice
Breakthrough: First-Ever Transcatheter Mitral Valve Replacement Gets CE Mark Approval - Stock Titan
Investors in Edwards Lifesciences Corporation Should Contact Levi & Korsinsky Before December 13, 2024 to Discuss Your RightsEW - marketscreener.com
Edwards Lifesciences Stock: A Deep Dive Into Analyst Perspectives (9 Ratings) - Benzinga
Truist Cuts Price Target on Edwards Lifesciences to $75 From $78, Keeps Hold Rating - marketscreener.com
Edwards Lifesciences’ Quarterly Earnings Preview: What You Need to Know - Nasdaq
Edwards Lifesciences’ Quarterly Earnings Preview: What You Need To Know - Barchart.com
Edwards lifesciences CVP Daniel Lippis sells $21,183 in stock By Investing.com - Investing.com Canada
Edwards lifesciences CVP Daniel Lippis sells $21,183 in stock - Investing.com
CMS rolls out draft coverage memo for TEER for the tricuspid valve - BioWorld MedTech
Citigroup Adjusts Edwards Lifesciences Price Target to $84 From $83, Maintains Buy Rating - MarketScreener
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry - Benzinga
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Medical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt - Morningstar
Edwards Lifesciences (NYSE:EW) Presents Promising AS Treatment Data At ACC Session - Yahoo Finance
Edwards’ Early TAVR refutes surveillance recs for aortic stenosis - BioWorld MedTech
Sands Capital Select Growth Fund Sold Edwards Lifesciences Corporation (EW) For Better Opportunities - Yahoo Home
Jim Cramer Calls Edwards Lifesciences (EW) a Hold – Prefers Boston Scientific Right Now! - Insider Monkey
Edwards shares data supporting timely TAVR intervention - MassDevice
Huntington Beach man meets heart valve engineers who saved his life - Los Angeles Times
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $85 From $92, Keeps Buy Rating - MarketScreener
Goldman Sachs Adjusts Price Target to Edwards Lifesciences to $85 From $92, Keeps Buy Rating - MarketScreener
Edwards Lifesciences CFO Scott Ullem sells $797,267 in stock - Investing.com
Edwards Lifesciences CFO Scott Ullem sells $797,267 in stock By Investing.com - Investing.com South Africa
Edwards Lifesciences: Double-Digit Top Line And EPS Growth Ahead - Seeking Alpha
S&P 500 Gains and Losses Today: Edwards Lifesciences Sinks on Outlook for Key Product - MSN
How Is The Market Feeling About Edwards Lifesciences? - Benzinga
Is Edwards Lifesciences Stock Underperforming the Nasdaq? - Nasdaq
Is Edwards Lifesciences Stock Underperforming The Nasdaq? - Barchart
Edwards Lifesciences downgraded at JPM, Truist on slower transcatheter valve growth - MSN
Edwards Lifesciences VP Donald Bobo Jr. sells $645,623 in stock By Investing.com - Investing.com Australia
Edwards Lifesciences VP Donald Bobo Jr. sells $645,623 in stock - Investing.com
1.93%
자본화:
|
볼륨(24시간):